{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:43:30Z","timestamp":1793378610234,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,8,26]],"date-time":"2017-08-26T00:00:00Z","timestamp":1503705600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"NYU CTSA from the National Center for the Advancement of Translational Science","award":["1UL1TR001445"],"award-info":[{"award-number":["1UL1TR001445"]}]},{"name":"Investigator Award from the Rheumatology Research Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s11926-017-0688-y","type":"journal-article","created":{"date-parts":[[2017,8,26]],"date-time":"2017-08-26T06:37:45Z","timestamp":1503729465000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":137,"title":["Gout and Metabolic Syndrome: a Tangled Web"],"prefix":"10.1007","volume":"19","author":[{"given":"Gabrielle E.","family":"Thottam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Krasnokutsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Pillinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,26]]},"reference":[{"issue":"4","key":"688_CR1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00296-009-1304-x","volume":"31","author":"HG Yoo","year":"2011","unstructured":"Yoo HG, Lee SI, Chae HJ, et al. Prevalence of insulin resistance and metabolic syndrome in patients with gouty arthritis. Rheumatol Int. 2011;31(4):485\u201391.","journal-title":"Rheumatol Int"},{"issue":"1","key":"688_CR2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2337\/dc10-0879","volume":"34","author":"A Mozumdar","year":"2011","unstructured":"Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006. Diabetes Care. 2011;34(1):216\u20139.","journal-title":"Diabetes Care"},{"issue":"10","key":"688_CR3","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","volume":"63","author":"Y Zhu","year":"2011","unstructured":"Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63(10):3136\u201341.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"688_CR4","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3949\/ccjm.73.12.1059","volume":"73","author":"M Heinig","year":"2006","unstructured":"Heinig M, Johnson RJ. Role of uric acid in hypertension, renal disease, and metabolic syndrome. Cleve Clin J Med. 2006;73(12):1059\u201364.","journal-title":"Cleve Clin J Med"},{"issue":"4","key":"688_CR5","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4103\/0022-3859.43509","volume":"54","author":"S Ouppatham","year":"2008","unstructured":"Ouppatham S, Bancha S, Choovichian P. The relationship of hyperuricemia and blood pressure in the Thai army population. J Postgrad Med. 2008;54(4):259\u201362.","journal-title":"J Postgrad Med"},{"issue":"12","key":"688_CR6","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1681\/ASN.2005050572","volume":"16","author":"DH Kang","year":"2005","unstructured":"Kang DH, Park SK, Lee IK, et al. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005;16(12):3553\u201362.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"688_CR7","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1159\/000087713","volume":"25","author":"DH Kang","year":"2005","unstructured":"Kang DH, Han L, Ouyang X, et al. Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol. 2005;25(5):425\u201333.","journal-title":"Am J Nephrol"},{"issue":"3","key":"688_CR8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/hrt.74.3.247","volume":"74","author":"KE Sorensen","year":"1995","unstructured":"Sorensen KE, Celermajer DS, Spiegelhalter DJ, et al. Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J. 1995;74(3):247\u201353.","journal-title":"Br Heart J"},{"issue":"3","key":"688_CR9","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1751-7176.2010.00406.x","volume":"13","author":"RD Brook","year":"2011","unstructured":"Brook RD, Yalavarthi S, Myles JD, et al. Determinants of vascular function in patients with chronic gout. J Clin Hypertens (Greenwich). 2011;13(3):178\u201388.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"1","key":"688_CR10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2215\/CJN.00350106","volume":"2","author":"AA Ejaz","year":"2007","unstructured":"Ejaz AA, Mu W, Kang DH, et al. Could uric acid have a role in acute renal failure? Clin J Am Soc Nephrol. 2007;2(1):16\u201321.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"688_CR11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.mehy.2008.01.017","volume":"71","author":"RJ Johnson","year":"2008","unstructured":"Johnson RJ, Gaucher EA, Sautin YY, et al. The planetary biology of ascorbate and uric acid and their relationship with the epidemic of obesity and cardiovascular disease. Med Hypotheses. 2008;71(1):22\u201331.","journal-title":"Med Hypotheses"},{"issue":"11","key":"688_CR12","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/rheumatology\/keq204","volume":"49","author":"B \u00c1lvarez-Lario","year":"2010","unstructured":"\u00c1lvarez-Lario B, Macarr\u00f3n-Vicente J. Uric acid and evolution. Rheumatology (Oxford). 2010;49(11):2010\u20135.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"688_CR13","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1161\/hy1101.092839","volume":"38","author":"M Mazzali","year":"2001","unstructured":"Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101\u20136.","journal-title":"Hypertension"},{"issue":"1","key":"688_CR14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1124\/pr.58.1.6","volume":"58","author":"P Pacher","year":"2006","unstructured":"Pacher P, Nivorozhkin A, Szab\u00f3 C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58(1):87\u2013114.","journal-title":"Pharmacol Rev"},{"issue":"8","key":"688_CR15","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jama.300.8.924","volume":"300","author":"DI Feig","year":"2008","unstructured":"Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300(8):924\u201332.","journal-title":"JAMA"},{"key":"688_CR16","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.cct.2016.08.016","volume":"50","author":"MB Saddekni","year":"2016","unstructured":"\u2022 Saddekni MB, Saag KG, Dudenbostel T, et al. The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationale. Contemp Clin Trials. 2016;50:238\u201344. This manuscript reports the study design of an improtant trial, currently recruiting patients for participation in an assessment of the potential of urate-lower therapy to control blood pressure in adults with essential hypertension.","journal-title":"Contemp Clin Trials"},{"key":"688_CR17","volume-title":"Department of Health and Human Services., Center for Disease Control., National Center for Health Statistics (U.S.). Health, United States, 2015 : with special feature on racial and ethnic health disparities","author":"United States","year":"2016","unstructured":"United States. Department of Health and Human Services., Center for Disease Control., National Center for Health Statistics (U.S.). Health, United States, 2015 : with special feature on racial and ethnic health disparities, vol. xv. Hyattsville: National Center for Health Statistics; 2016. 449 pages p"},{"issue":"3","key":"688_CR18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0895-4356(88)90127-8","volume":"41","author":"RD Abbott","year":"1988","unstructured":"Abbott RD, Brand FN, Kannel WB, et al. Gout and coronary heart disease: the Framingham study. J Clin Epidemiol. 1988;41(3):237\u201342.","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"688_CR19","doi-asserted-by":"crossref","first-page":"e0145193","DOI":"10.1371\/journal.pone.0145193","volume":"10","author":"JH Chen","year":"2015","unstructured":"\u2022\u2022 Chen JH, Lan JL, Cheng CF, et al. Effect of urate-lowering therapy on all-cause and cardiovascular mortality in hyperuricemic patients without gout: a case-matched cohort study. PLoS One. 2015;10(12):e0145193. This study reports the results of an extremely large, \u201cbig data\u201d-based study of all-cause and cardiovascular mortality in untreated hyperuricemic patients compared with those receiving urate-lowering therapy on mortality risk. Treated hyperuricemic patients experienced a lower rate of all cause and cardiovascular death, suggesting that uarate lowering therapy may affect survival.","journal-title":"PLoS One"},{"issue":"9","key":"688_CR20","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.3899\/jrheum.141542","volume":"42","author":"JH Chen","year":"2015","unstructured":"Chen JH, Lan JL, Cheng CF, et al. Effect of urate-lowering therapy on the risk of cardiovascular disease and all-cause mortality in patients with gout: a case-matched cohort study. J Rheumatol. 2015;42(9):1694\u2013701.","journal-title":"J Rheumatol"},{"issue":"5","key":"688_CR21","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1136\/annrheumdis-2012-202972","volume":"74","author":"L Grimaldi-Bensouda","year":"2015","unstructured":"Grimaldi-Bensouda L, Alp\u00e9rovitch A, Aubrun E, et al. Impact of allopurinol on risk of myocardial infarction. Ann Rheum Dis. 2015;74(5):836\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"688_CR22","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1136\/heartjnl-2014-306670","volume":"101","author":"FJ Abajo de","year":"2015","unstructured":"de Abajo FJ, Gil MJ, Rodr\u00edguez A, et al. Allopurinol use and risk of non-fatal acute myocardial infarction. Heart. 2015;101(9):679\u201385.","journal-title":"Heart"},{"issue":"4","key":"688_CR23","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1047-2797(97)00204-4","volume":"8","author":"W Rathmann","year":"1998","unstructured":"Rathmann W, Funkhouser E, Dyer AR, et al. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary artery risk development in young adults. Ann Epidemiol. 1998;8(4):250\u201361.","journal-title":"Ann Epidemiol"},{"key":"688_CR24","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40200-015-0200-z","volume":"14","author":"S Nejatinamini","year":"2015","unstructured":"Nejatinamini S, Ataie-Jafari A, Qorbani M, et al. Association between serum uric acid level and metabolic syndrome components. J Diabetes Metab Disord. 2015;14:70.","journal-title":"J Diabetes Metab Disord"},{"issue":"10","key":"688_CR25","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1093\/rheumatology\/ken305","volume":"47","author":"HK Choi","year":"2008","unstructured":"Choi HK, De Vera MA, Krishnan E. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology (Oxford). 2008;47(10):1567\u201370.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"688_CR26","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1136\/ard.2010.130013","volume":"69","author":"G Rodr\u00edguez","year":"2010","unstructured":"Rodr\u00edguez G, Soriano LC, Choi HK. Impact of diabetes against the future risk of developing gout. Ann Rheum Dis. 2010;69(12):2090\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"688_CR27","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/annrheumdis-2014-206410","volume":"75","author":"CF Kuo","year":"2016","unstructured":"\u2022 Kuo CF, Grainge MJ, Mallen C, et al. Comorbidities in patients with gout prior to and following diagnosis: case-control study. Ann Rheum Dis. 2016;75(1):210\u20137. This article reports that patients with gout tend to have increasing development of co-morbidities after their gout diagnosis, suggesting a possible direction of causality between gout and metabolic syndrome.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"688_CR28","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/0003-4819-143-7-200510040-00009","volume":"143","author":"HK Choi","year":"2005","unstructured":"Choi HK, Mount DB, Reginato AM, et al. Pathogenesis of gout. Ann Intern Med. 2005;143(7):499\u2013516.","journal-title":"Ann Intern Med"},{"issue":"8","key":"688_CR29","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1253\/circj.69.928","volume":"69","author":"TW Yoo","year":"2005","unstructured":"Yoo TW, Sung KC, Shin HS, et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J. 2005;69(8):928\u201333.","journal-title":"Circ J"},{"issue":"4","key":"688_CR30","first-page":"188","volume":"10","author":"A Qui\u00f1ones-Galvan","year":"1997","unstructured":"Qui\u00f1ones-Galvan A, Ferrannini E. Renal effects of insulin in man. J Nephrol. 1997;10(4):188\u201391.","journal-title":"J Nephrol"},{"issue":"1","key":"688_CR31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3181\/00379727-166-41033","volume":"166","author":"FW Scott","year":"1981","unstructured":"Scott FW, Trick KD, Stavric B, et al. Uric acid-induced decrease in rat insulin secretion. Proc Soc Exp Biol Med. 1981;166(1):123\u20138.","journal-title":"Proc Soc Exp Biol Med"},{"issue":"1","key":"688_CR32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/cphy.c130024","volume":"4","author":"L Rui","year":"2014","unstructured":"Rui L. Energy metabolism in the liver. Compr Physiol. 2014;4(1):177\u201397.","journal-title":"Compr Physiol"},{"issue":"3","key":"688_CR33","doi-asserted-by":"crossref","first-page":"F625","DOI":"10.1152\/ajprenal.00140.2005","volume":"290","author":"T Nakagawa","year":"2006","unstructured":"Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2006;290(3):F625\u201331.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"8","key":"688_CR34","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1097\/JIM.0000000000000242","volume":"63","author":"M Takir","year":"2015","unstructured":"\u2022\u2022 Takir M, Kostek O, Ozkok A, et al. Lowering uric acid with allopurinol improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia. J Investig Med. 2015;63(8):924\u20139. This small clinical trial tests the possibility that urate lowering in patients with asymptomatic hyperuricemia may directly improve their metabolic state, in the form of decreased insulin resistance, as well as systemic inflammation.","journal-title":"J Investig Med"},{"issue":"1","key":"688_CR35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1758-5996-4-3","volume":"4","author":"TH Kim","year":"2012","unstructured":"Kim TH, Lee SS, Yoo JH, et al. The relationship between the regional abdominal adipose tissue distribution and the serum uric acid levels in people with type 2 diabetes mellitus. Diabetol Metab Syndr. 2012;4(1):3.","journal-title":"Diabetol Metab Syndr"},{"issue":"10","key":"688_CR36","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431\u201346.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"688_CR37","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/annrheumdis-2013-203970","volume":"73","author":"N Dalbeth","year":"2014","unstructured":"\u2022 Dalbeth N, Chen P, White M, et al. Impact of bariatric surgery on serum urate targets in people with morbid obesity and diabetes: a prospective longitudinal study. Ann Rheum Dis. 2014;73(5):797\u2013802. Dalbeth et al report that weight loss surgery results in clinically relevant reductions in serum urate.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"688_CR38","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.soard.2014.02.025","volume":"10","author":"H Romero-Talam\u00e1s","year":"2014","unstructured":"Romero-Talam\u00e1s H, Daigle CR, Aminian A, et al. The effect of bariatric surgery on gout: a comparative study. Surg Obes Relat Dis. 2014;10(6):1161\u20135.","journal-title":"Surg Obes Relat Dis"},{"issue":"4","key":"688_CR39","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.2337\/db10-0916","volume":"60","author":"W Baldwin","year":"2011","unstructured":"\u2022\u2022 Baldwin W, McRae S, Marek G, et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes. 2011;60(4):1258\u201369. This study analyzes the effect of urate on a mouse model of metabolic syndrome. The study found that alterations in urate could affect components of the metabolic syndrome, including including insulin resistance and systemic and adipose inflammation.","journal-title":"Diabetes"},{"issue":"4","key":"688_CR40","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jfma.2012.11.014","volume":"114","author":"MH Shih","year":"2015","unstructured":"Shih MH, Lazo M, Liu SH, et al. Association between serum uric acid and nonalcoholic fatty liver disease in the US population. J Formos Med Assoc. 2015;114(4):314\u201320.","journal-title":"J Formos Med Assoc"},{"issue":"3","key":"688_CR41","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.metabol.2012.08.013","volume":"62","author":"JC Sirota","year":"2013","unstructured":"Sirota JC, McFann K, Targher G, et al. Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: liver ultrasound data from the National Health and Nutrition Examination Survey. Metabolism. 2013;62(3):392\u20139.","journal-title":"Metabolism"},{"issue":"4","key":"688_CR42","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/ajcn\/86.4.899","volume":"86","author":"RJ Johnson","year":"2007","unstructured":"Johnson RJ, Segal MS, Sautin Y, et al. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr. 2007;86(4):899\u2013906.","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"688_CR43","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ijo.2009.259","volume":"34","author":"SE Perez-Pozo","year":"2010","unstructured":"Perez-Pozo SE, Schold J, Nakagawa T, et al. Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response. Int J Obes. 2010;34(3):454\u201361.","journal-title":"Int J Obes"},{"issue":"1","key":"688_CR44","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1210\/er.2008-0033","volume":"30","author":"RJ Johnson","year":"2009","unstructured":"Johnson RJ, Perez-Pozo SE, Sautin YY, et al. Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes? Endocr Rev. 2009;30(1):96\u2013116.","journal-title":"Endocr Rev"},{"issue":"5 Suppl","key":"688_CR45","doi-asserted-by":"crossref","first-page":"754S","DOI":"10.1093\/ajcn\/58.5.754S","volume":"58","author":"PA Mayes","year":"1993","unstructured":"Mayes PA. Intermediary metabolism of fructose. Am J Clin Nutr. 1993;58(5 Suppl):754S\u201365S.","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"688_CR46","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/art.23245","volume":"59","author":"JW Choi","year":"2008","unstructured":"Choi JW, Ford ES, Gao X, et al. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2008;59(1):109\u201316.","journal-title":"Arthritis Rheum"},{"issue":"7639","key":"688_CR47","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/bmj.39449.819271.BE","volume":"336","author":"HK Choi","year":"2008","unstructured":"Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ. 2008;336(7639):309\u201312.","journal-title":"BMJ"},{"issue":"10","key":"688_CR48","doi-asserted-by":"crossref","first-page":"e47948","DOI":"10.1371\/journal.pone.0047948","volume":"7","author":"MA Lanaspa","year":"2012","unstructured":"Lanaspa MA, Sanchez-Lozada LG, Cicerchi C, et al. Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver. PLoS One. 2012;7(10):e47948.","journal-title":"PLoS One"},{"issue":"11","key":"688_CR49","doi-asserted-by":"crossref","first-page":"e48801","DOI":"10.1371\/journal.pone.0048801","volume":"7","author":"MA Lanaspa","year":"2012","unstructured":"Lanaspa MA, Cicerchi C, Garcia G, et al. Counteracting roles of AMP deaminase and AMP kinase in the development of fatty liver. PLoS One. 2012;7(11):e48801.","journal-title":"PLoS One"},{"issue":"1","key":"688_CR50","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/annrheumdis-2014-206074","volume":"75","author":"Y Wang","year":"2016","unstructured":"\u2022 Wang Y, Viollet B, Terkeltaub R, et al. AMP-activated protein kinase suppresses urate crystal-induced inflammation and transduces colchicine effects in macrophages. Ann Rheum Dis. 2016;75(1):286\u201394. This study underlines the important role of AMPK\u2019s on inflammatory response, and suggests a novel mechanism of colchicine as a stimulator of AMPK.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"688_CR51","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4065\/81.7.925","volume":"81","author":"CA Sarawate","year":"2006","unstructured":"Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006;81(7):925\u201334.","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"688_CR52","first-page":"1575","volume":"31","author":"AA Riedel","year":"2004","unstructured":"Riedel AA, Nelson M, Joseph-Ridge N, et al. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol. 2004;31(8):1575\u201381.","journal-title":"J Rheumatol"},{"issue":"2","key":"688_CR53","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s11926-010-0154-6","volume":"13","author":"NL Edwards","year":"2011","unstructured":"Edwards NL. Quality of care in patients with gout: why is management suboptimal and what can be done about it? Curr Rheumatol Rep. 2011;13(2):154\u20139.","journal-title":"Curr Rheumatol Rep"},{"issue":"12","key":"688_CR54","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1080\/15257770.2011.596496","volume":"30","author":"H Yamanaka","year":"2011","unstructured":"Yamanaka H. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1018\u201329.","journal-title":"Nucleosides Nucleotides Nucleic Acids"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-017-0688-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-017-0688-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-017-0688-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T14:01:53Z","timestamp":1719410513000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-017-0688-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,26]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["688"],"URL":"https:\/\/doi.org\/10.1007\/s11926-017-0688-y","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,26]]},"article-number":"60"}}